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Abstract: Acorus calamus L. is  used as anti-inflammatory remedy in traditional system of medicine in Pakistan and India. This study was 
designed to explore the anti-inflammatory mechanism of Acorus calamus L. and its underlying signaling pathways. Aqueous, butanolic and 
n-hexane fractions of Acorus calamus were tested against cyclooxygenase (COX) and lipoxygenase (LOX) mediated eicosanoids production 
by arachidonic acid (AA). Butanolic fraction of Acorus calamus, but not the aqueous and n-hexane fractions, inhibited the COX mediated 
production of thromboxane B2 (TXB2) and liopxygenase product 1 (LP1) -a metabolite of LOX pathway. 12-(hydroxyeicosatetraenoic acid) 
HETE- another product of the LOX pathway was unaffected by all three fractions. Butanolic fraction of Acorus calamus showed strong 
inhibition against AA-induced platelet aggregation. Investigation of the underlying signaling pathways revealed that butanolic fraction 
inhibited phospholipase C (PLC) pathway in platelets, most probably acting on protein kinase C (PKC). Aqueous and n-hexane fractions of 
Acorus calamus were not effective against any platelet agonist. This study shows that butanolic fraction of Acorus calamus possesses 
components that inhibit AA metabolism and platelet aggregation through multiple pathways.  
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Resumen: Acorus calamus L. se utiliza como remedio anti-inflamatorio en el sistema tradicional de la medicina en Pakistán y la India. Este 
estudio fue diseñado para explorar el mecanismo anti-inflamatorio de Acorus calamus L. y sus vías de señalización subyacentes. Fracciones 
acuosa, butanólica y de n-hexano de Acorus calamus se ensayaron frente a la ciclooxigenasa (COX) y de la lipoxigenasa (LOX) mediada 
por la producción de eicosanoides por el ácido araquidónico (AA). La fracción butanólica de Acorus calamus, pero no las fracciones acuosas 
y de n-hexano, inhibieron la producción de COX mediada por tromboxano B2 (TXB2) y el producto lipoxigenasa 1 (LP1) - un metabolito 
de la vía de LOX, 12 - (ácido hidroxieicosatetraenoico) HETE - otro producto de la ruta de LOX no fue afectado por  las tres fracciones. La 
fracción butanólica de Acorus calamus mostró una fuerte inhibición contra la agregación plaquetaria inducida por AA. La investigación de 
las vías de señalización subyacentes reveló que la fracción butanólica inhibió la fosfolipasa C (PLC) y la vía en las plaquetas, probablemente 
actuando sobre la proteína quinasa C (PKC). Fracciones acuosas y de n - hexano de Acorus calamus no fueron eficaces contra ningún 
agonista de plaquetas. Este estudio muestra que la fracción butanólica de Acorus calamus posee componentes que inhiben el metabolismo 
del AA y la agregación plaquetaria a través de múltiples vías. 
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Introduction 
Acorus calamus L. (Araceae) is found in the northern 
areas of Pakistan, in India, Central Asia, North 
America and Eastern Europe. In England, it is present 
as a wild plant on the edges of lakes and streams 
(Wallis, 1985) and has become widely diffused due to 
cultivation. It is a perennial herb with a creeping and 
much branched aromatic rhizome (Kapoor, 1990). 
Rhizome of Acorus calamus L. is widely used 
as anti-inflammatory agent in the Indian systems of 
medicine, such as Ayurveda, Siddha and Unani 
(Meena et al., 2010). It is also frequently used as nerve 
tonic and as an emetic (Baquar, 1989).  It is used in 
low grade remittent fever, in colic pain, in 
inflammation, in dyspepsia (Kapoor, 1990) and in 
diarrhea, flatulence and asthma. It is usually used as a 
decoction at a dose of 1-3 g (Usmanghani et al., 1997) 
or 2-7 g as powdered rhizome (Duke, 2002).  
Many pharmacological activities of the genus 
Acorus are known including Acorus tatarinowii, 
showing antidepressant (Han et al., 2013) and anti-
fatigue activity (Zhu et al., 2012),  while 
anticonvulsant activity is reported from Acorus 
gramineous (Chen et al., 2013) and anti-melanogenic 
and antioxidant activities from Acorus macropadiceus 
(Huang et al., 2012). However, Acorus calamus has 
been repoted for most of the activities. Acorus 
calamus extract has been used in traditional Chinese 
prescription due to its beneficial effects in memory 
disorder and on learning performance while anti-aging 
effect in senescence has also been reported 
(Nishiyama et al., 1994;  Zhang et al., 1994).  
Acorus calamus L. also finds its use in the 
Ayurvedic system of medicine, where it is used for the 
treatment of epilepsy, hysteria, insomnia, melancholia, 
neurosis, loss of memory and remittent fevers (Kirtikar 
and Basu, 1956; Agarwal et al., 1956). Ethanolic 
extract of rhizome of this plant possesses sedative, 
analgesic, moderately hypotensive and respiratory 
depressant properties (Agarwal et al., 1956). Many 
other activities have been reported from this plant 
including, antifungal (Rajput and Karuppayil, 2012), 
anti-inflammatory (Kim et al., 2009; Tiwari et al., 
2010) and antispasmodic through calcium channel 
blockade (Gilani et al., 2006). Hot water (HW), 
butylene glycol (BG), hexane (HE) and steam distilled 
(SD) extracts of Acorus calamus showed different 
cytoxicity levels evaluated in RBL-2H3 cells (Kim et 
al., 2012a). 
Studies on chemical composition of Acorus spp. have 
revealed that α- and β-asarones are the major active 
components (Lee et al., 2010; Geng et al., 2010). Ten 
(10) compounds were isolated by Qiao et al., (2012) 
from the Acorus calamus, many of which for the first 
time from this genus. A bioassay-guided fractionation 
and chemical investigation of the MeOH extract from 
the rhizomes of Acorus gramineus resulted in the 
isolation and identification of thirteen phenolic 
derivatives (Kim et al., 2012b) including two new 8-
O-4'-neolignans, named surinamensinols A and B and 
a new phenolic compound, named acoramol. Using 
supercritical fluid extraction, Dang et al., (2011) 
isolated two new compounds, (E)- and (Z)-
diastereomers of α-asarone and β-asarone from Acorus 
tatarinowii Schott and purified by high-speed counter-
current chromatography with a two-phase solvent 
system composed of n-hexane-ethyl acetate-methanol-
water (1:0.2:1:0.3, v/v). 
Acorus calamus L. is used in India and 
Pakistan for its anti-inflammatory effects (Baquar, 
1989; Kapoor, 1990). However, the underlying 
mechanisms of these anti-inflammatory effects are not 
known. Since arachidonic acid (AA) metabolites 
formed via cyclooxygenase (COX) and lipoxygenase 
(LOX) play important roles in inflammation, we 
hypothesized that the observed anti-inflammatory 
effects of Acorus calamus may be mediated through 
inhibition of COX and LOX enzymes. We further 
investigated the effects of Acorus calamus on human 
platelet aggregation induced by a diverse set of platelet 
agonists. 
 
MATERIAL AND METHODS 
All organic solvents, chemicals and reagents used in 
the experiments were of analytical and highest purity 
grade. All the chemicals are purchased from Sigma 
chemical company, St. Louis, USA except 
14
C 
arachidonic acid which was purchased from 
Amersham Biosciences; acetic acid and citric acid 
from BDH, sodium phosphate (mono and dibasic) 
from Merck and m-3M3FBS was purchased from 
Calbiochem (La Jolla, CA, USA). 
 
Extraction of plant material 
Fresh rhizomes of Acorus calamus L. (2 kg) were 
collected from Swat District, K.P.K Pakistan, and 
authenticated by Dr. Humera Gul, Assistant Professor 
of the Department of Botany, University of Karachi, 
Pakistan. The plant material was ground using a 
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commercial grinder to obtain fine powder. Five 
hundred (500) grams of ground material was soaked in 
5 liter aqueous methanol and left for 24 hours at 4º C. 
The extract was filtered using a filtration flask and 
whattmann paper. This extract was evaporated on a 
rotary evaporator under reduced pressure (-760 mm 
Hg) to a thick, semi-solid mass of dark brown color 
i.e. crude extract.  
 
Fractionation of the crude extract 
One hundred grams of the extract was dissolved in 
distilled water. This was then introduced in a 
separating funnel. n-hexane (50-70 ml) was then added 
into the same separating funnel. This mixture was 
shaken vigorously, regularly allowing the air to escape 
out. It was kept for about 30 min to let the two layers 
separate. The upper layer of n-hexane was acquired 
and the same procedure was repeated twice and all the 
n-hexane layers were collected and concentrated in a 
rotary evaporator to obtain the n-hexane fraction. 
Butanol (50 ml) was then added to the remaining layer 
and the same process was repeated as with n-hexane, 
finally obtaining the butanol fraction, the yield of both 
fractions was 23.6% and 30%, respectively, while the 
remaining layer was filtered using a filtration flask and 
whattmann paper and used in the experiments as 
aqueous fraction. 
 
Arachidonic acid metabolism by human platelets 
Archidonic acid metabolism and thromboxane B2 
(TXB2) formation was studied using a Berthold T.L.C. 
linear analyzer and chromatography data system 
(Model LKB 511, Berthold, W. Germany) as 
described previously (Saeed et al., 2007a; Saeed et al., 
2007b). Human blood platelets were obtained in 
plastic bags containing 30-40 ml concentrated platelet 
rich plasma (PRP) from the diagnostic laboratory of 
the Aga Khan University, Karachi. The PRP was 
centrifuged at 1200 g for 20 min and the sedimented 
platelets were washed twice with an ice-cold 
phosphate buffer (50 mM, PH 7.4), containing NaCl 
(0.15 M) and EDTA (0.2 mM).  
After centrifugation platelets were re-
suspended in the same buffer without EDTA at the 
initial PRP concentration. The PRP suspension was 
homogenized at 4º C using a polytron homogenizer for 
15 sec and the homogenate centrifuged at 1200g for 20 
min. Supernatant (300 µl containing 0.4 mg protein) 
was incubated with 10 µg unlabelled AA and 0.1 µCi 
[1-
14
C]AA in the presence and absence of test fraction. 
After 15 min of gentle shaking in air at 37º C the 
reaction was stopped by adding 0.4 ml citric acid (0.4 
M) and ethyl acetate (7.0 ml). After mixing and 
centrifuging at 600 g for 5 min at 4º C, the organic 
layer was separated and evaporated to dryness under 
nitrogen. Residues were dissolved in 40 µl of ethanol 
and 20 µl was applied to silica gel G thin layer 
chromatography (TLC) plates. The AA, TXB2 (a stable 
degradation product of TXA2), LP1 and 12-HETE 
standards were plotted separately.  
 
Solvent Systems for Developing TLC Plates 
The TLC plates were developed in ether/petroleum 
ether [boiling range 40-60]/acetic acid (50:50:1, v/v) 
to a distance of 17 cm. By use of this solvent system 
the various lipoxygenasse products such as 12-
hydroxy-eicosatetraenoic acid (HETE) were separated 
with TXB2 and prostaglandins remaining at the origin. 
The solvent system used for the separation of TXB2 
was ethyl acetate/iso-octane/water/acetic acid 
(11:5:10:2, v/v upper phase). Radioactive zones were 
located and quantified by use of a TLC linear analyzer 
and chromatography data system.  
 
Preparation of platelets 
Platelet effects were studied in human platelets by 
taking blood via venipuncture from normal human 
volunteers reported to be free of medication for 7 days. 
Blood sample were mixed with 3.8% (w/v) sodium 
citrate solution (9:1) and centrifuged at 260 × g for 15 
min at 20º C to obtain platelet-rich plasma (PRP). The 
remaining blood samples were centrifuged at 1200 × g 
for 10 min to obtain platelet-poor plasma (PPP). 
Platelet count was determined by phase contrast 
microscopy and all aggregation studies were carried 
out at 37º C with PRP having platelet counts between 
2.5 and 3.0 × 10
8
 ml
–1
 of plasma.  
 
Measurement of platelet aggregation 
Aggregation was monitored using dual-channel Lumi- 
aggregometer (Model 400 Chronolog Corporation, 
Chicago, USA) using 0.45 ml aliquots of PRP (Saaed 
et al., 2007a; Saeed et al., 2007b). The final volume 
was made up to 0.5 ml with the test fraction. 
Aggregation was induced by AA (1.7 mM), ADP (2.2 
μM), PAF (0.8 μM), PLC (with 30 μM m-3M3FBS), 
PKC (with 100 ng/ml PMA), IP3 (30 μM). The 
antiplatelet effects of test fractions were studied by 
pretreatment of PRP with each fraction for 2 min 
followed by addition of platelet agonist. The resulting 
aggregation was recorded for 5 min after challenge by 
the change in light transmission as a function of time. 
The number of experiments (n) with each agonist is 
indicated in the table 1 and ranged 3-5. After 
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establishing the anti-platelet activity against various 
agonists, dose-response curves were constructed to 
calculate the 1C50 values.  
 
Statistical Analysis 
Statistical analysis of the results was done by 
Students’s t test. The differences were considered 
significants between the means of two groups when 
the p value was found below 0.05 (p < 0.05). 
 
RESULTS AND DISCUSSION 
Inflammation is a common sign of many life-
threatening pathologies (Aldridge, 2002; Zia-Ul-Haq 
et al., 2013) and lipid peroxidation is a characteristic 
feature of inflammation (Cook, 2005). During 
inflammation oxidative metabolites of AA play an 
important role (Kubala et al., 2010). Activation of the 
phospholipase A2 in response to various stimuli 
releases AA, which are then metabolised by two major 
enzymatic pathways: COX and LOX, leading to pro-
inflammatory mediators, prostaglandins (PGs) and 
leukotrienes (LTs), respectively (Marruchella et al., 
2010). PGs and LTs are potent inflammatory 
mediators and regulate immune responses and 
physiological processes such as bronchoconstriction, 
vasodilation and mucus secretion (Gilroy et al., 1999; 
Kumar et al., 2007). 
Anti-inflammatory activity of the Acorus 
calamus has been reported a few years ago (Kim et al., 
2009, Tiwari et al., 2010). However, the mechanism 
was not known. Kim et al., (2009) found that Acorus 
calamus inhibited the interleukin (IL)-6 and IL-8 as 
well as nuclear factor κB. Most of the anti-
inflammatory drugs available in the market inhibit 
prostaglandin synthesis and this might be the 
mechanism of action of Acorus calamus (Tiwari et al., 
2010). Our study, therefore, explored whether the 
inhibition of the prostaglandin synthesis can account 
for the observed anti-inflammatory effects of Acorus 
calamus. 
Aqueous fraction of Acorus calamus was 
found to be completely ineffective against both COX 
and LOX pathways as indicated by the lack of 
inhibition of TXB2, LP1 and 12-HETE. However, its 
butanolic fraction inhibited the COX metabolite TXB2 
and one of the LOX metabolites-LP1 (Figure 1). The 
other LOX metabolite -12-HETE remained unaffected. 
n-hexane fraction was also ineffective against COX 
and LOX pathways. This indicates that butanolic 
fraction of Acorus calamus contains constituents 
which completely inhibit the COX pathway while 
partially blocking the LOX pathway of AA 
metabolism. Butanolic fraction inhibited the formation 
of TXB2 and LP1 with IC50 value (mg ± SEM) of 0.80 
± 0.10 and 1.05 ± 0.07 respectively (Table 1 and 
Figure 1). The standard, asprin, completely inhibited 
both COX and LOX pathways at 200 µM, and 
indomethacin at 500 µM while the negative control, 
saline was unable to significantly inhibit any pathway.  
Inhibition of the COX mediated formation of TXB2 by 
butanolic fraction indicates that COX inhibitory 
components are concentrated in the butanolic fraction 
of Acorus calamus. This action of Acorus calamus is 
similar to nonsteroidal anti-inflammatory drugs 
(NSAIDs) such as aspirin, which also directly target 
COX. Aspirin inhibited TXB2 with IC50 of 11 ± 0.21 
(mg ± SEM) and LP1 with 25 ± 4.3 (mg ± EM).  
It is becoming increasingly evident that blood 
platelets do not
 
only exert important functions in 
hemostasis and thrombus formation
 
but are also 
involved in atherosclerotic vascular disease (Weber, 
2005). Platelets play a critical role in the initial 
restriction of blood loss following vascular injury by 
rapidly adhering to exposed subendothelial matrix 
components and aggregating to form a provisional 
plug. Since TXB2 was inhibited by butanolic fraction, 
we hypothesized that it would be effective against AA-
induced human platelet aggregation as AA induces 
platelet aggregation after it is converted by COX into 
TXA2. Butanolic fraction indeed inhibited the human 
platelet aggregation induced by AA with IC50 value 
(mg ± SEM) of 0.08 ± 0.004 (Figure 2 and Table 1). 
In this study, only the butanolic fraction of 
Acorus calamus was active against AA-induced 
platelet aggregation but at a concentration 10-times 
lower than required for inhibition of TXB2 formation 
through COX pathway. This indicates the involvement 
of other mechanisms of platelet inhibition besides 
COX pathway. 
Receptor for TXA2 is a G-protein coupled 
receptor which primarily stimulates Gq and activates 
phospholipase C (PLC) (Nakahata, 2008). PLC 
converts phosphtidylinositol biphosphate (PIP2) into 
inositol triphosphate (IP3) and diacylglycerol (DAG). 
DAG remains in the plane of the membrane to 
stimulate PKC while IP3 travels through the cytoplasm 
to endoplasmic reticulum where it releases calcium 
(Berridge and Irvine, 1984; Nishizuka, 1984). Both of 
these effects i.e., activation of PKC and release of 
calcium can initiate and enhance platelet aggregation 
(Brass et al., 1993; Heemskerk and Sage, 1997). 
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Figure 1 
Figure shows the effects of butanolic fraction of Acorus calamus on AA metabolism suggesting dose-
dependant inhibition (n = 4). 
 
 
 
Butanolic fraction inhibited PLC-induced (30 µM m-
3M3FBS) platelet aggregation with IC50 value (mg ± 
SEM) of 0.46 ± 0.13 (Figure 2 and Table 1), indicating 
that apart from inhibiting COX pathway butanolic 
fraction also inhibits PLC pathway in platelets. In 
order to further explore whether PLC itself is inhibited 
or downstream effectors are implicated, we used PMA 
and IP3 induced platelet aggregation to evaluate their 
contribution in the antiplatelet actions of the butanolic 
fraction. Although only 50% inhibition (IC50 value of 
2.56 ± 0.40 (mg ± SEM)) was observed against IP3-
induced (30 µM) platelet aggregation, butanolic 
fraction potently and completely inhibited PMA-
induced (100 ng/ml) platelet aggregation (IC50 value 
0.52 ± 0.18 (mg ± SEM). This suggests that butanolic 
fraction inhibits platelet aggregation by interfering not 
only with COX but PKC as well. 
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Metabolite IC50 (mg ± SEM) 
Against AA metabolism 
TXB2 0.80 ± 0.10 (n = 4) 
LP1 1.05 ± 0.07 (n = 4) 
Against platelet aggregation 
Platelet agonist IC50 (mg ± SEM) 
AA 0.080 ± 0.04 (n = 5) 
PLC (Induced by 3M3FBS) 0.460 ± 0.13 (n = 4) 
PKC (Induced by PMA) 0.520 ± 0.18 (n = 5) 
IP3 2.560 ± 0.40 (n = 3) 
PAF 0. 0.16 (n = 3) 
ADP 1.200 ± 0.21 (n = 4) 
 
Table 1 
IC50 values of the butanolic fraction of Acorus calamus against AA metabolism and human platelet 
aggregation induced by a diverse set of agonists. 
 
 
 
Butanolic fraction was further evaluated against PAF 
and ADP induced human platelet aggregation as these 
platelet agonists stimulate PLC downstream of their 
receptors. Since PAF induces platelet aggregation 
exclusively by binding to its receptor and stimulating 
PLC and subsequently PKC and IP3, it was found to 
be potently inhibited by the butanolic fraction with 
IC50 value (mg ± SEM) of 0.55 ± 0.16 (Figure 2 and 
Table 1). However, ADP induced aggregation was 
inhibited at much higher concentrations and complete 
inhibition was not observed. This might be due to the 
fact that ADP induces platelet aggregation by 
stimulating G12 as well. 
Our study does not identify the compounds 
responsible for the observed pharmacological 
activities by the Acorus calamus. However, it can be 
safely said that compounds such as isocalamendiol, 
asarone, acoradin, acrogermacrone, and 
preisocalamendiol, etc. are not responsible for these 
effects as these compounds are present in highly non-
polar factions such as n-hexane, ether, benzene, ethyl 
acetate and chloroform (Raja et al., 2009)  while in the 
current investigation, the activities were mainly 
observed in the butanolic fraction. Therefore, the most 
likely candidates responsible for these activities may 
be triterpenoid saponins, phenyl derivatives, 
dihydroxy phenols such as galangin etc as these 
compounds are present predominantly in alcoholic 
fractions of the plant (Raja et al., 2009). 
In this study the pharmacological activity was 
found to be concentrated mainly in the butanolic 
fraction and not in the aqueous or n-hexane fraction. 
This suggests that the active compounds responsible 
for these activities are slightly non-polar in nature.  
The lack of activity in the aqueous fraction is 
understandable as the pharmacological targets in this 
investigation are intracellular, and for polar 
compounds it is not easy to pass through the lipids of 
plasma membrane to get access to the intracellular 
targets. 
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Figure 2 
Butanolic fraction of the Acorus calamus inhibits platelet aggregation induced  
by various platelet agonists, (n = 4). 
 
 
 
 
CONCLUSION 
It appears that AA metabolism inhibitory constituents 
as well as platelet inhibitory constituents are 
concentrated in the butanolic fraction of the Acorus 
calamus. Therefore, it is likely that traditionally 
reported anti-inflammatory activities of Acorus 
calamus are mediated through inhibition of COX, 
LOX and PKC pathways. This new information 
provides a theoretical basis for development of new 
anti-inflammatory approaches targeted to COX, LOX 
and PKC activity. Since no effective inhibitor is 
currently available to block the COX, LOX and PKC 
pathways simultaneously, compounds isolated from 
Acorus calamus might be valuable in the future for 
treatment and prevention of a number of inflammatory 
conditions. 
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